Detalhe da pesquisa
1.
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.
Am J Hematol
; 97(12): E470-E473, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36111658
2.
Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.
Eur J Haematol
; 97(6): 576-582, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27157440
3.
Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Ann Hematol
; 93(12): 1985-92, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24985089
4.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia
; 35(2): 485-493, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33414483
5.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Blood Cancer J
; 11(2): 21, 2021 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33563901
6.
Second versus first wave of COVID-19 in patients with MPN.
Leukemia
; 36(3): 897-900, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35064223
7.
Long-term follow-up of recovered MPN patients with COVID-19.
Blood Cancer J
; 11(6): 115, 2021 06 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34135309
8.
RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution.
J Oncol
; 2012: 412742, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-23049552